Silo Pharma announced positive results for its preclinical study evaluating SP-26. This is a novel extended-release ketamine implant. Results from the preclinical study indicate SP-26 is a safe, well-tolerated, and long-acting treatment for fibromyalgia.

These implants are designed to deliver ketamine at a controlled rate, avoiding the dissociative effects associated with IV injection and providing a viable alternative to addictive opioid treatments. With these preclinical results in place, Silo will now advance toward clinical studies and expand its pipeline for chronic pain and mental health indications. Check it out: https://finance.yahoo.com/news/silo-pharma-sp-26-ketamine-121100819.html

A new study published in the journal Nature Mental Health has suggested that depression in young teens may be more treatable than in adults, thanks to more flexible and less entrenched symptom patterns. 

Using data from more than 35,000 adolescents, researchers applied network analysis and a novel “network temperature” model to show that depressive symptoms stabilize with age, becoming more resistant to change.

Scientists say these findings highlight the importance of targeting depression at an early age, while symptoms are still changing. Current interventions for depression treat overall depression severity and do not consider how symptoms interact and evolve over time.

Here’s what lead author Dr. Poppy Grimes had to say …

What’s exciting about this study is the introduction of a novel approach to capture how depression symptoms interact and evolve over time, offering a fresh lens for understanding mental health in young people.

You can read more about this study here: https://www.nature.com/articles/s44220-025-00415-5

Researchers at the University of Turku, Finland, identified a new biomarker in multiple sclerosis.

According to a new study published in Nature Medicine, the thickness of the inflammatory rim surrounding brain lesions predicts how quickly and severely the disease progresses. By combining PET imaging and post-mortem brain analysis, the study showed that thicker rims lead to more aggressive brain damage.

Authors of the study say this discovery could enable earlier identification of patients needing intensive treatment and help assess the effectiveness of new therapies. Here’s more: https://www.nature.com/articles/s41591-025-03625-7 

Did you know that psilocybin may be an effective treatment for repeated concussions?

According to researchers at Boston’s Northeastern University, psilocybin could have great potential as a treatment for concussions due to its brain-healing properties.  This discovery comes after conducting a study where rats with head injuries were dosed with psilocybin. Following the psilocybin treatment, protein analysis revealed that psilocybin caused a decrease in phosphorylated tau, a modified form of the tau protein that plays a significant role in brain function, especially in maintaining the structure of nerve cells or neurons. 

This is important, as phosphorylated tau has been implicated in several neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia, Parkinson’s disease, and chronic traumatic encephalopathy. Another protein, brain-derived neurotrophic factor (BDNF), which is vital to neuronal survival and growth, was also increased post-psilocybin. Check it out: https://pmc.ncbi.nlm.nih.gov/articles/PMC11838531/